Quick Answer
Organogenesis Holdings Inc. reported Total Revenue of $564.17 million for the year ending 2025.
- Organogenesis Holdings Inc. showed an increase of +17.0% in Total Revenue from 2024 to 2025.
- This data is from Organogenesis Holdings Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2017: $39.84 million | Q2 2017: $54.07 million | Q3 2017: $51.46 million | Q4 2017: $53.14 million | Q1 2018: $35.53 million | Q2 2018: $43.55 million | Q3 2018: $50.77 million | Q4 2018: $63.60 million | Q1 2019: $57.12 million | Q2 2019: $64.95 million | Q3 2019: $64.27 million | Q1 2020: $61.73 million | Q2 2020: $68.96 million | Q3 2020: $100.80 million | Q1 2021: $102.55 million | Q2 2021: $123.20 million | Q3 2021: $113.75 million | Q1 2022: $97.12 million | Q2 2022: $121.40 million | Q3 2022: $116.86 million | Q1 2023: $107.64 million | Q2 2023: $117.32 million | Q3 2023: $108.53 million | Q1 2024: $109.98 million | Q2 2024: $130.23 million | Q3 2024: $115.18 million | Q1 2025: $86.69 million | Q2 2025: $101.01 million | Q3 2025: $150.86 million.
- Over the full 10 years of available data (2016 to 2025), Organogenesis Holdings Inc.'s Total Revenue has grown by 306.7%.
- Historical annual values: Fiscal year 2025: $564.17 million | Fiscal year 2024: $482.04 million | Fiscal year 2023: $433.14 million | Fiscal year 2022: $450.89 million | Fiscal year 2021: $467.36 million | Fiscal year 2020: $338.30 million | Fiscal year 2019: $260.98 million | Fiscal year 2018: $193.45 million | Fiscal year 2017: $198.51 million | Fiscal year 2016: $138.73 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: